Guardian Pharmacy Services (GRDN) Set to Post Quarterly Earnings on Thursday

Guardian Pharmacy Services (NYSE:GRDN) is expected to be releasing its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect Guardian Pharmacy Services to post earnings of $0.3146 per share and revenue of $365.76 million for the quarter. Individuals may visit the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Guardian Pharmacy Services (NYSE:GRDN) last issued its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The company had revenue of $351.77 million during the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. On average, analysts expect Guardian Pharmacy Services to post $1.18 EPS for the current fiscal year and $1.33 EPS for the next fiscal year.

Guardian Pharmacy Services Price Performance

Shares of NYSE:GRDN opened at $40.93 on Wednesday. The company’s 50 day simple moving average is $41.18 and its 200 day simple moving average is $38.10. The stock has a market capitalization of $2.04 billion, a price-to-earnings ratio of 39.74, a price-to-earnings-growth ratio of 2.09 and a beta of 0.06. Guardian Pharmacy Services has a 1 year low of $26.34 and a 1 year high of $48.33.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on GRDN. Oppenheimer raised their target price on Guardian Pharmacy Services from $43.00 to $49.00 and gave the company an “outperform” rating in a report on Friday, August 7th. KeyCorp began coverage on Guardian Pharmacy Services in a report on Tuesday, September 22nd. They set an “overweight” rating and a $52.00 price target for the company. Wall Street Zen downgraded Guardian Pharmacy Services from a “buy” rating to a “hold” rating in a research report on Sunday, October 25th. Weiss Ratings lowered Guardian Pharmacy Services from a “buy (b)” rating to a “buy (b-)” rating in a research note on Friday, October 23rd. Finally, Truist Financial lifted their target price on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Nine investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $45.57.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc is a provider of pharmacy services focused primarily on residents of long-term care and other institutional healthcare settings. Through its network of pharmacies, the company supplies prescription medications and related pharmacy support to assisted living communities, skilled nursing facilities, behavioral health organizations, and other care providers.

The company’s services include medication dispensing and packaging, prescription delivery, medication management, clinical pharmacy support, and technology-enabled tools designed to help caregivers and healthcare professionals manage residents’ medication regimens.